ACEP Announces Susan Sedory as its Next Executive Director

The American College of Emergency Physicians (ACEP) is pleased to announce that Susan Sedory, MA, CAE, will be its next Executive Director. As the next step in a career dedicated to improving health care, Ms. Sedory will build on the foundation laid by Dean Wilkerson, JD, MBA, CAE, who will retire as ACEP’s Executive Director on July 31, 2020.

As Executive Director, Ms. Sedory will oversee ACEP’s daily operations and advance the College’s advocacy, education and policy goals to empower emergency physicians and strengthen the field of emergency medicine. Ms. Sedory will be ACEP’s fourth executive director—and first female in this position—in the College’s more than 50-year history.

“I am honored to help the passionate leaders and members of ACEP, as well as all emergency physicians, achieve their vision for the future of emergency care,” Ms. Sedory said.

“Each day brings new opportunities and new pressures on physicians. But when those who are most passionate about their profession and their patients find their voice and community in their professional association, the momentum to sustain positive change is powerful.

“This is true now more than ever we face the public health crisis of the century. Together, we must ensure patients, systems, policymakers and physicians have the answers and resources they need.”

Ms. Sedory has been the Executive Director of the Society of Interventional Radiology since 2011, leading the association of more than 8,100 interventional radiology physicians, scientists and clinical professionals in the shared goal to optimize minimally invasive patient care. Ms. Sedory also spent 10 years at the American Academy of Otolaryngology in various positions, including Chief Strategy Officer, and started her career as a researcher at the National Institute on Deafness and Other Communication Disorders at the National Institutes of Health.

“Sue brings abundant experience as the leader of medical associations, as well as a significant background in research to the College,” said ACEP President William Jaquis, MD, FACEP.  “Her thoughtful and incisive leadership style will serve us well as we move through and beyond this current COVID-19 crisis to a newly defined era of emergency medicine.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”